Company / Operating Income per Share
Summit Therapeutics Inc. Operating Income per Share History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$0.32
FY2024
5-year range
-$2.89 / -$0.26
FY2020-FY2024
Trend
+88.8%
vs FY2023
Sector context
#68 of 201
Health Care
What the data says
At $-0.32, Summit Therapeutics Inc.'s operating income per share ranks #68 of 201 in the Health Care sector. Operating Income per Share returned to growth in FY2024 after 2 years of decline, reaching $-0.32.
Based on SEC 10-K filings.
-0.32 in FY2024.
Improved from $-0.88 to $-0.32 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#68 of 201 in Health CareTop 34% of 201This company -$0.32 Sector average -$28.56
▼
+98.9% above sector average
Key checks
Key Insights
- In FY2024, operating income per share increased 88.8% year-over-year.
- Ranks #68 out of 201 companies in the Health Care sector.
- Peak operating income per share was recorded in FY2018.
- Lowest operating income per share in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | -$0.32 | +88.8% |
| FY2023 | -$2.89 | -228.5% |
| FY2022 | -$0.88 | -242.9% |
| FY2021 | -$0.26 | +67.6% |
| FY2020 | -$0.79 | +5.4% |
| FY2019 | -$0.84 | -367.5% |
| FY2018 | $0.31 | - |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026